Klaviyo price target raised to $48 from $41 at Wells Fargo
Wells Fargo raised the firm’s price target on Klaviyo (KVYO) to $48 from $41 and keeps an Equal Weight rating on the shares. The firm notes ...
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...